Effectiveness of hospital-based oral dextrose gel in prevention and treatment of asymptomatic newborns at risk of hypoglycemia
Issued Date
2024-01-01
Resource Type
ISSN
14767058
eISSN
14764954
Scopus ID
2-s2.0-85190377006
Journal Title
Journal of Maternal-Fetal and Neonatal Medicine
Volume
37
Issue
1
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Maternal-Fetal and Neonatal Medicine Vol.37 No.1 (2024)
Suggested Citation
Rattanamalee R., Nuntnarumit P. Effectiveness of hospital-based oral dextrose gel in prevention and treatment of asymptomatic newborns at risk of hypoglycemia. Journal of Maternal-Fetal and Neonatal Medicine Vol.37 No.1 (2024). doi:10.1080/14767058.2024.2341310 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/98042
Title
Effectiveness of hospital-based oral dextrose gel in prevention and treatment of asymptomatic newborns at risk of hypoglycemia
Author(s)
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Objective: To evaluate the effectiveness of using hospital-based 40% dextrose gel (DG) in preventing and treating asymptomatic hypoglycemia in infants of diabetic mothers (IDM), large for gestational age (LGA), and macrosomic neonates. Methods: A medical chart review was conducted to compare data between before (April 2018 to March 2019, epoch 1) and after (September 2020 to November 2021, epoch 2) 40% DG implementation. DG, prepared by the hospital pharmaceutical unit, was applied within 30–45 min after birth, and three additional doses could be repeated during the first 6 h of life in combination with early feeding. The primary outcome was the rate of intravenous dextrose administration. Secondary outcomes were the incidence of hypoglycemia, first capillary blood glucose concentrations, and the length of hospital stay. Results: Six hundred forty-three at-risk newborns were included (320 before and 323 after implementation of DG). Maternal and neonatal baseline characteristics were not different between the two epochs. The incidence of hypoglycemia was not different (17.8% in before versus 14.6% in after implementation, p = 0.26). The rate of intravenous dextrose administration after DG implementation was significantly lower than that before DG implementation (3.4% versus 10.3%, p < 0.001, risk reduction ratio = 0.33, 95% CI = 0.17–0.64). The length of hospital stay was not different between the two epochs. Conclusions: Implementing a protocol for administration of hospital-based 40% DG can reduce the need of intravenous dextrose administration among IDM, LGA and macrosomic neonates.